5 May 2021 in Journal of Experimental Medicine
The pioneer transcription factor (TF) PU.1 controls hematopoietic cell fate by decompacting stem cell heterochromatin and allowing nonpioneer TFs to enter otherwise inaccessible genomic sites. PU.1 deficiency fatally arrests lymphopoiesis and myelopoiesis in mice, but human congenital PU.1 disorders have not previously been described. We studied six unrelated agammaglobulinemic patients, each harboring a heterozygous mutation (four de novo, two unphased) of SPI1, the gene encoding PU.1. Affected patients lacked circulating B cells and possessed few conventional dendritic cells. Introducing disease-similar SPI1 mutations into human hematopoietic stem and progenitor cells impaired early in vitro B cell and myeloid cell differentiation. Patient SPI1 mutations encoded destabilized PU.1 proteins unable to nuclear localize or bind target DNA. In PU.1-haploinsufficient pro–B cell lines, euchromatin was less accessible to nonpioneer TFs critical for B cell development, and gene expression patterns associated with the pro– to pre–B cell transition were undermined. Our findings molecularly describe a novel form of agammaglobulinemia and underscore PU.1’s critical, dose-dependent role as a hematopoietic euchromatin gatekeeper.
1 April 2016 in Journal of the American College of Surgeons
The initial experience with ABO incompatible (ABOi) orthotopic liver transplantations (OLTs) was dismal. In the current study, we investigated whether ABOi pediatric OLTs could achieve acceptable patient outcomes. The option for ABOi transplantation is vital because critically ill children have limited access to donor liver allografts. Kaplan-Meier and multivariate Cox analysis was performed on data collected from 13,179 pediatric OLT recipients in the United Network for Organ Sharing database, including 540 ABOi recipients. We also analyzed 18 pediatric recipients of ABOi OLTs at Texas Children's Hospital. Recipients were divided into 2 groups: transplanted between 1987 to 2002 (remote era) and 2002 to 2013 (modern era). Analysis revealed 4 main points. First, there was a significant (p < 0.01) improvement in ABOi OLT survival in the modern era. Second, threshold analysis revealed superior outcomes (p < 0.01) for OLT recipients younger than 2 years of age. Third, survival outcomes for ABOi and ABO-identical OLTs were the same for recipients younger than 2 years: ABOi was 91.8% (1 year) and 88.4% (5 year), and ABO identical was 91.5% (1 year) and 86.7% (5 year) (p = 0.94). Lastly, we found identical OLT results when analyzing our own institutional experience. To date, there has been a 92.9% survival rate in the modern era compared with 75% in the remote era. All recipients younger than 2 years (n = 9) are still alive, compared with 78% of those older than 2 years. This analysis revealed a significant improvement in the survival of ABOi liver transplant recipients in the modern era. Importantly, ABOi liver transplantation can be performed in recipients younger than 2 years of age with equivalent outcomes compared with ABO-identical recipients.
23 May 2023 in Clinical Immunology
NDNatalia Fernandez Davila
17 August 2026 in Pediatric Transplantation
Background: Antibody‐mediated rejection (AMR) in pediatric liver transplantation (LT) is uncommon and poorly understood. While human leukocyte antigen (HLA) antibodies are usually implicated in AMR, non‐HLA antibodies have also been reported. Methods: We describe a 7‐year‐old female with non‐HLA AMR in the setting of positive angiotensin type 1 receptor (AT1R) antibodies. Results: She was diagnosed with acute T‐cell mediated rejection (TCMR) 6 months post‐LT which was treated with intravenous methylprednisolone (IVMP) but had minimal response. A repeat biopsy revealed features of AMR including C4d staining and capillaritis, but donor‐specific antibodies (DSAs) were negative. However, AT1R antibodies were elevated at 21 U/mL. She received antithymocyte globulin (ATG) and was started on losartan to block AT1R antibodies, with excellent response. Conclusion: While the recognition and mechanisms of AMR in pediatric LT are in its infancy, this case highlights the importance of considering non‐HLA antibodies as potential mediators of AMR. Children who fail to respond to TCMR treatment should be evaluated for AMR by obtaining DSAs, C4d staining on biopsy, and non‐HLA antibodies.
30 October 2026 in Annals of Allergy, Asthma & Immunology